Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1/2 Multi-center Study Evaluating the Safety and Efficacy of Axicabtagene Ciloleucel in Combination With Utomilumab in Subjects With Refractory Large B-Cell Lymphoma

Trial Profile

A Phase 1/2 Multi-center Study Evaluating the Safety and Efficacy of Axicabtagene Ciloleucel in Combination With Utomilumab in Subjects With Refractory Large B-Cell Lymphoma

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 26 Dec 2018

At a glance

  • Drugs Axicabtagene ciloleucel (Primary) ; Utomilumab (Primary) ; Cyclophosphamide; Fludarabine
  • Indications B-cell lymphoma; Diffuse large B cell lymphoma
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms ZUMA-11
  • Sponsors Kite Pharma
  • Most Recent Events

    • 30 Nov 2018 Status changed from not yet recruiting to recruiting.
    • 10 Oct 2018 Status changed from planning to not yet recruiting.
    • 22 Jan 2018 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top